MITAC-COMPUTING
27.5.2019 04:02:06 CEST | Business Wire | Press release
TYAN® , an industry-leading server platform design manufacturer and a subsidiary of MiTAC Computing Technology Corporation, will be exhibiting a full line of HPC, storage and cloud computing server platforms that are optimized for HPC, enterprise and datacenter markets at Computex 2019 from May 28th to June 1st , Booth # L0631a in Taipei, Taiwan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190526005002/en/
“The increasingly growing demand for AI is transforming the data center and is resulting in a tremendous amount of data being pulled into big data platforms at massive scale,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. “TYAN’s leading portfolio of HPC, storage and cloud server platforms are based on the 2nd gen Intel® Xeon® Scalable processors and are designed to help enterprises and data center service providers capture, process, and analyze big data faster and at a more powerful rate than ever before.”
2nd Gen Intel Xeon Scalable Processors Empower TYAN HPC and Storage Platforms to Deliver Leading Performance
TYAN’s HPC and storage server platforms are built on the 2nd gen Intel Xeon Scalable processors with accompanying new innovations of Intel® Deep Learning Boost technology and Intel® Optane™ DC persistent memory that enable faster machine learning application execution and accelerated workload processing and service delivery. The new Thunder HX FT83-B7119 is an AI-optimized platform and is ideal for AI training and inference applications. The system supports for up to 3TB of memory and 12 hot-swappable 3.5” drives in a 4U enclosure.
The Thunder SX FA100-B7118 is TYAN’s flagship storage server supporting dual-socket 2nd gen Intel Xeon Scalable processors and 100 3.5” drives in a 4U rackmount form factor. The platform is designed for both cold storage and large-scale object storage applications such as Lustre. TYAN’s Thunder SX TN76-B7102 is 2U dual-socket 2nd gen Intel Xeon Scalable processor-based storage platform. With support for up to 24 DDR4 DIMM slots and maximum expansion up to 8 standard PCIe slots, the TN76-B7102 can fully address the high memory capacity required by data virtualization and in-memory databases.
For the high-performance storage segment, the Thunder SX GT62H-B7106 is a 1U server platform with support hot-swap all-flash drives. The GT62H-B7106 features dual-socket 2nd gen Intel Xeon Scalable processors, 16 DIMM slots, two low profile PCIe x16 slots, and 10 U.2 NVMe drive bays. This platform offers maximum storage performance and large memory capacity and is ideal for edge server applications.
The new Thunder SX GT90-B7113 features support for dual 2nd gen Intel Xeon Scalable processors, 12 hot-swap 3.5” drives mounted to a service drawer and 4 hot-swap NVMe U.2 drive bays in a 35” deep 1U chassis. The platform perfectly matches CSP server-based software-defined storage applications by allowing serviceability and density within the same server.
Intel ® Xeon ® D-2100 and Intel ® Xeon ® E-2100 Processor-based Platforms to Maximize Compute Performance and Efficiency for Cloud and Storage
Powered by the Intel Xeon D-2100 processors, TYAN Thunder SX TE70-B5546 and Thunder SX TE73-B5546 platforms are optimized to deliver rich features of low-power, high-density and high-availability. These two systems are both in 2U dual-node form factor with dual-controller, dual-path redundant design for high availability requirement and support dual-port SAS/NVMe storage functions for today’s high available data-intensive storage environments. TE70-B5546 supports up to 24 2.5” dual-port SAS 12Gb/s drive bays and 4 of bays supports dual-port NVMe U.2; TE73-B5546 supports up to 12 3.5” dual-port SAS 12Gb/s drive bays and 4 of bays supports dual-port NVMe U.2.
Moreover, taking full advantage of Intel Xeon E-2100 processors, TYAN offers increased reliability, security, performance, and affordability for its entry server lineup. TYAN’s Thunder CX GT24E-B5556 is a 1U single-socket Intel Xeon E-2100 processor-based edge cloud server. With support for up to 4 DDR4 DIMM slots, 3 PCIe slots, and dual 10GBase-T Ethernet ports, the platform is optimized for cost-effective cloud gaming applications. The Thunder CX GX38-B5550 is 1U single-socket Intel Xeon E-2100 processor-based compact sever with shallow chassis and support for 2 3.5” internal SATA drive bays for IoT applications.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190526005002/en/
Contact:
MiTAC Computing Technology Corporation/ TYAN Business Unit Fenny Chen fenny.chen@tyan.com.tw
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom